December 2016
-
Submit abstracts for posters and podium presentations by July 26, 2013 at http://www.ddl-conference.org.uk/?q=abstractsubmissionDDL24 Full guidelines available at http://www.ddl-conference.org.uk/files2/Abstract_Guidelines_2013.pdf. Read more . . .
-
According to reports, Johnson & Johnson described development of a ketamine nasal spray for the treatment of depression during a meeting with analysts on May 23, 2013. The product is not listed among the company’s… Read more . . .
-
Despite most delegates having partied past midnight at the previous night’s gala dinner, the 8:30 a.m. session on “Designing Devices for the Marketplace” Day 3 of RDD Europe 2013 was very well attended. . .… Read more . . .
-
On Day 2 of RDD Europe 2013, the focus was primarily on regulatory issues. . . . Read more Read more . . .
-
A new consortium described as a “series of conceptual research projects in the area of nasal physiology, function and drug delivery” that “aims to enhance understanding in the area of upper respiratory tract disorders and… Read more . . .
-
On the morning of May 22, one of the organizers of RDD Europe 2013, Peter Byron, opened the meeting by welcoming approximately 470 delegates back to Berlin.. . . Read more Read more . . .
-
A study presented at ATS 2013 found that over 40 percent of uninsured patients treated for COPD at a US clinic did not actually have COPD. Researchers from Northeast Ohio Medical University and Saint Elizabeth… Read more . . .
-
Prosonix has started a Phase 2 safety and dose-ranging study of PSX1002 inhaled glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA), in patients with moderate-to-severe COPD, the company has announced. The suspension formulation of PSX1002 engineered… Read more . . .
-
Grifols is paying $25 million upfront, plus up to $25 million in milestone payments to acquire a worldwide license for Aradigm’s Pulmaquin and Lipoquin inhaled ciprofloxacin formulations. Grifols will also pay tiered royalties on worldwide… Read more . . .
-
Malvern Instruments has announced that it will team up with Proveris Scientific Corporation on a nasal spray characterization system called Solo for Spraytec, which combines Proveris’s automated actuator and software for precise control of device… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland